Alterity Therapeutics (Alterity Therapeutics) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Alterity Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Alterity Therapeutics's Free Cash Flow for the three months ended in Dec. 2023 was $-3.26 Mil. Alterity Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Alterity Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Alterity Therapeutics's current FCF Yield % is -27.13%.

The historical rank and industry rank for Alterity Therapeutics's FCF Margin % or its related term are showing as below:

During the past 13 years, the highest FCF Margin % of Alterity Therapeutics was -3725.00%. The lowest was -6158.19%. And the median was -4826.95%.

ATHE's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -143.92
* Ranked among companies with meaningful FCF Margin % only.

Alterity Therapeutics FCF Margin % Historical Data

The historical data trend for Alterity Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alterity Therapeutics FCF Margin % Chart

Alterity Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

FCF Margin %

Get a 7-Day Free Trial

Alterity Therapeutics Quarterly Data
	Jun18	Dec18	Jun19	Sep19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Alterity Therapeutics's FCF Margin %

For the Biotechnology subindustry, Alterity Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alterity Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Alterity Therapeutics's FCF Margin % falls into.

Alterity Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Alterity Therapeutics's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-13.452	/	0
	=	%

Alterity Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-3.255	/	0
	=	%

Alterity Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Alterity Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Alterity Therapeutics (Alterity Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alterity Therapeutics Ltd (NAS:ATHE) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

PBN:Germany ATH:Australia

Address

350 Collins Street, Level 14, Melbourne, VIC, AUS, 3000

Website

https://www.alteritytherapeutics.com

Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.